Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage

Molecular Pharmacology

Volumn 80, Issue 6, 2011, Pages 1000-1012

  Lin, Z Ping ^a   Lee, Yashang ^a   Lin, Fang ^a   Belcourt, Michael F ^a   Li, Peining ^a   Cory, Joseph G ^b   Glazer, Peter M ^a   Sartorelli, Alan C ^a  

^a YALE CANCER CENTER   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; PROTEIN SUBUNIT; RAD51 PROTEIN; RIBONUCLEOTIDE REDUCTASE;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; DNA DAMAGE; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMALS; CELL DIVISION; CISPLATIN; DEOXYADENINE NUCLEOTIDES; DNA DAMAGE; G2 PHASE; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HOMOLOGOUS RECOMBINATION; HUMANS; LUCIFERASES, RENILLA; RIBONUCLEOTIDE REDUCTASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 81555210968     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.074708     Document Type: Article

References (49)

1. Arnaudeau C, Lundin C, and Helleday T (2001) DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 307:1235-1245. (Pubitemid 33027636)
2. Avkin S, Sevilya Z, Toube L, Geacintov N, Chaney SG, Oren M, and Livneh Z (2006) p53 and p21 regulate error-prone DNA repair to yield a lower mutation load. Mol Cell 22:407-413.
3. Bartek J and Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429. (Pubitemid 38340288)
4. Baumann P and West SC (1998) Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 23:247-251. (Pubitemid 28343368)
5. Bertino JR (2009) Cancer research: from folate antagonism to molecular targets. Best Pract Res Clin Haematol 22:577-582.
6. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, and Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899-23903. (Pubitemid 30624678)
7. Chabes AL, Pfleger CM, Kirschner MW, and Thelander L (2003) Mouse ribonucleotide reductase R2 protein: a new target for anaphase-promoting complex-Cdh1-mediated proteolysis. Proc Natl Acad Sci USA 100:3925-3929. (Pubitemid 36418133)
8. Cleaver JE and States JC (1997) The DNA damage-recognition problem in human and other eukaryotic cells: the XPA damage binding protein. Biochem J 328:1-12. (Pubitemid 27499433)
9. Engström Y, Eriksson S, Jildevik I, Skog S, Thelander L, and Tribukait B (1985) Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem 260:9114-9116. (Pubitemid 15249885)
10. Eriksson S and Martin DW, Jr. (1981) Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2. J Biol Chem 256:9436-9440. (Pubitemid 12234705)
11. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, and Reedijk J (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24:707-713.
12. Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, and Sartorelli AC (2000) Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59:983-991. (Pubitemid 30110814)
13. Friedberg EC (2005) Suffering in silence: the tolerance of DNA damage. Nat Rev Mol Cell Biol 6:943-953.
14. Friedberg EC, Wagner R, and Radman M (2002) Specialized DNA polymerases, cellular survival, and the genesis of mutations. Science 296:1627-1630. (Pubitemid 34579143)
15. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, et al. (2003) Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278:20303-20312. (Pubitemid 36799229)
16. Hunting DJ and Dresler SL (1985) Dependence of u.v.-induced DNA excision repair on deoxyribonucleoside triphosphate concentrations in permeable human fibroblasts: a model for the inhibition of repair by hydroxyurea. Carcinogenesis 6:1525-1528. (Pubitemid 16238950)
17. Janz C and Wiesmüller L (2002) Wild-type p53 inhibits replication-associated homologous recombination. Oncogene 21:5929-5933. (Pubitemid 35007244)
18. Kim H, Chen J, and Yu X (2007) Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 316:1202-1205. (Pubitemid 46877484)
19. Kumari A, Schultz N, and Helleday T (2004) p53 protects from replication-associated DNA double-strand breaks in mammalian cells. Oncogene 23:2324-2329. (Pubitemid 38496787)
20. Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, and Kinsella TJ (2010) Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine- 2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res 16:1298-1306.
21. Kuzminov A (2001) Single-strand interruptions in replicating chromosomes cause double-strand breaks. Proc Natl Acad Sci USA 98:8241-8246.
22. Lin X and Howell SB (2006) DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 5:1239-1247. (Pubitemid 43881316)
23. Lin ZP, Belcourt MF, Carbone R, Eaton JS, Penketh PG, Shadel GS, Cory JG, and Sartorelli AC (2007) Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. Biochem Pharmacol 73:760-772. (Pubitemid 46227329)
24. Lin ZP, Belcourt MF, Cory JG, and Sartorelli AC (2004) Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem 279:27030-27038. (Pubitemid 38812539)
25. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, et al. (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448-1459. (Pubitemid 30421838)
26. Lundin C, Schultz N, Arnaudeau C, Mohindra A, Hansen LT, and Helleday T (2003) RAD51 is involved in repair of damage associated with DNA replication in mammalian cells. J Mol Biol 328:521-535. (Pubitemid 36442689)
27. Martin RF, Radford I, and Pardee M (1977) Accumulation of short DNA fragments in hydroxyurea treated mouse L-cells. Biochem Biophys Res Commun 74:9-15. (Pubitemid 8012953)
28. Mekeel KL, Tang W, Kachnic LA, Luo CM, DeFrank JS, and Powell SN (1997) Inactivation of p53 results in high rates of homologous recombination. Oncogene 14:1847-1857. (Pubitemid 27207686)
29. Mishina Y, Ayusawa D, Seno T, and Koyama H (1991) Thymidylate stress induces homologous recombination activity in mammalian cells. Mutat Res 246:215-220.
30. Mu D, Hsu DS, and Sancar A (1996) Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 271:8285-8294. (Pubitemid 26108661)
31. Muniandy PA, Liu J, Majumdar A, Liu ST, and Seidman MM (2010) DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol 45:23-49.
32. Nordlund P and Reichard P (2006) Ribonucleotide reductases. Annu Rev Biochem 75:681-706. (Pubitemid 44118048)
33. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, and Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858-5868. (Pubitemid 28124064)
34. Sandrini MP and Piskur J (2005) Deoxyribonucleoside kinases: two enzyme families catalyze the same reaction. Trends Biochem Sci 30:225-228. (Pubitemid 40693862)
35. Selden JR, Dolbeare F, Clair JH, Nichols WW, Miller JE, Kleemeyer KM, Hyland RJ, and DeLuca JG (1993) Statistical confirmation that immunofluorescent detection of DNA repair in human fibroblasts by measurement of bromodeoxyuridine incorporation is stoichiometric and sensitive. Cytometry 14:154-167. (Pubitemid 23042738)
36. Sibghatullah, Husain I, Carlton W, and Sancar A (1989) Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract. Nucleic Acids Res 17:4471-4484.
37. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279. (Pubitemid 37487159)
38. Snyder RD (1984) The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea. Mutat Res 131:163-172.
39. Sonoda E, Sasaki MS, Morrison C, Yamaguchi-Iwai Y, Takata M, and Takeda S (1999) Sister chromatid exchanges are mediated by homologous recombination in vertebrate cells. Mol Cell Biol 19:5166-5169. (Pubitemid 29289554)
40. Sørensen CS, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J, and Helleday T (2005) The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7:195-201. (Pubitemid 40268135)
41. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, and Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404:42-49. (Pubitemid 30143125)
42. Taylor WR and Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20:1803-1815. (Pubitemid 32458690)
43. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, and Chaney SG (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-3585. (Pubitemid 28376554)
44. Vogelstein B, Lane D, and Levine AJ (2000) Surfing the p53 network. Nature 408:307-310.
45. Wang D and Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320. (Pubitemid 41130944)
46. Werness BA, Levine AJ, and Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
47. Zdraveski ZZ, Mello JA, Marinus MG, and Essigmann JM (2000) Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol 7:39-50. (Pubitemid 30141924)
48. Zhao H, Watkins JL, and Piwnica-Worms H (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 99:14795-14800. (Pubitemid 35334563)
49. Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, Shih J, Hwu EB, Luh F, and Yen Y (2003) The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 63:6583-6594. (Pubitemid 37322936)